Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775873 | 0.87 | CA9 (0.39) | RPS6KA2CA9KMORPS6KA3ADORA3 | |
| SCHEMBL16785561 | 0.81 | FGFR4 (0.36) | CA9KMOPRMT5WDR77 | |
| SCHEMBL16775872 | 0.80 | PIK3CA (0.33) | KMORPS6KA3CCNT1CDK9 | |
| SCHEMBL16775871 | 0.80 | EGFR (0.33) | RPS6KA2KMORPS6KA3 | |
| SCHEMBL16775917 | 0.80 | GRM5 (0.40) | GRM5RPS6KA2KMOADORA3ADORA1 | |
| SCHEMBL16775921 | 0.79 | FGFR4 (0.37) | RPS6KA2CA9KMOADORA3ADORA2A | |
| SCHEMBL19865037 | 0.79 | GRM5 (0.36) | GRM5 | |
| SCHEMBL16776109 | 0.79 | KARS1 (0.38) | GRM5ADORA3ADORA1 | |
| SCHEMBL16775880 | 0.79 | RPS6KA3 (0.35) | RPS6KA2KMORPS6KA3CDK9 | |
| SCHEMBL16776022 | 0.79 | RPS6KA2 (0.41) | RPS6KA2CA9KMOADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 3471/4885RPS6KA2 2318/4885CA9 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.